The risk of radionecrosis after SRS and fSRS can be modeled as a function of dose and volume treated. The use of fSRS appears to reduce risks of radionecrosis for larger treatment volumes relative to SRS.
Int J Radiat Oncol Biol Phys 2021 May 1;110(1):68-86. doi: 10.1016/j.ijrobp.2020.08.013. Epub 2020 Sep 11.
Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain
Michael T Milano 1, Jimm Grimm 2, Andrzej Niemierko 3, Scott G Soltys 4, Vitali Moiseenko 5, Kristin J Redmond 6, Ellen Yorke 7, Arjun Sahgal 8, Jinyu Xue 9, Anand Mahadevan 2, Alexander Muacevic 10, Lawrence B Marks 11, Lawrence R Kleinberg 6Affiliations expand
- PMID: 32921513
- DOI: 10.1016/j.ijrobp.2020.08.013
Abstract
Purpose: As part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) after hypofractionated radiation therapy, data from published reports (PubMed indexed 1995-2018) were pooled to identify dosimetric and clinical predictors of radiation-induced brain toxicity after single-fraction stereotactic radiosurgery (SRS) or fractionated stereotactic radiosurgery (fSRS).
Methods and materials: Eligible studies provided NTCPs for the endpoints of radionecrosis, edema, or symptoms after cranial SRS/fSRS and quantitative dose-volume metrics. Studies of patients with only glioma, meningioma, vestibular schwannoma, or brainstem targets were excluded. The data summary and analyses focused on arteriovenous malformations (AVM) and brain metastases.
Results: Data from 51 reports are summarized. There was wide variability in reported rates of radionecrosis. Available data for SRS/fSRS for brain metastases were more amenable to NTCP modeling than AVM data. In the setting of brain metastases, SRS/fSRS-associated radionecrosis can be difficult to differentiate from tumor progression. For single-fraction SRS to brain metastases, tissue volumes (including target volumes) receiving 12 Gy (V12) of 5 cm3, 10 cm3, or >15 cm3 were associated with risks of symptomatic radionecrosis of approximately 10%, 15%, and 20%, respectively. SRS for AVM was associated with modestly lower rates of symptomatic radionecrosis for equivalent V12. For brain metastases, brain plus target volume V20 (3-fractions) or V24 (5-fractions) <20 cm3 was associated with <10% risk of any necrosis or edema, and <4% risk of radionecrosis requiring resection.
Conclusions: The risk of radionecrosis after SRS and fSRS can be modeled as a function of dose and volume treated. The use of fSRS appears to reduce risks of radionecrosis for larger treatment volumes relative to SRS. More standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses that can refine predictive models of brain toxicity risks.
Similar articles
- The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases.Gutschenritter T, Venur VA, Combs SE, Vellayappan B, Patel AP, Foote M, Redmond KJ, Wang TJC, Sahgal A, Chao ST, Suh JH, Chang EL, Ellenbogen RG, Lo SS.Cancers (Basel). 2020 Dec 29;13(1):70. doi: 10.3390/cancers13010070.PMID: 33383817 Free PMC article. Review.
- Single- and Multi-Fraction Stereotactic Radiosurgery Dose Tolerances of the Optic Pathways.Milano MT, Grimm J, Soltys SG, Yorke E, Moiseenko V, Tomé WA, Sahgal A, Xue J, Ma L, Solberg TD, Kirkpatrick JP, Constine LS, Flickinger JC, Marks LB, El Naqa I.Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):87-99. doi: 10.1016/j.ijrobp.2018.01.053. Epub 2018 Jan 31.PMID: 29534899
- Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases.Redmond KJ, Gui C, Benedict S, Milano MT, Grimm J, Vargo JA, Soltys SG, Yorke E, Jackson A, El Naqa I, Marks LB, Xue J, Heron DE, Kleinberg LR.Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):53-67. doi: 10.1016/j.ijrobp.2020.10.034. Epub 2020 Dec 31.PMID: 33390244
- Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases.Jhaveri J, Chowdhary M, Zhang X, Press RH, Switchenko JM, Ferris MJ, Morgan TM, Roper J, Dhabaan A, Elder E, Eaton BR, Olson JJ, Curran WJ, Shu HG, Crocker IR, Patel KR.J Neurosurg. 2018 Apr 20;130(3):797-803. doi: 10.3171/2017.9.JNS171735.PMID: 29676690 Free PMC article.
- The radiation oncologist’s perspective on stereotactic radiosurgery.Regine W.Technol Cancer Res Treat. 2002 Feb;1(1):43-9. doi: 10.1177/153303460200100106.PMID: 12614176 Review.
Cited by 4 articles
- Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer.Jablonska PA, Bosch-Barrera J, Serrano D, Valiente M, Calvo A, Aristu J.Cancers (Basel). 2021 Apr 29;13(9):2141. doi: 10.3390/cancers13092141.PMID: 33946751 Free PMC article. Review.
- Current status and recent advances in resection cavity irradiation of brain metastases.Minniti G, Niyazi M, Andratschke N, Guckenberger M, Palmer JD, Shih HA, Lo SS, Soltys S, Russo I, Brown PD, Belka C.Radiat Oncol. 2021 Apr 15;16(1):73. doi: 10.1186/s13014-021-01802-9.PMID: 33858474 Free PMC article. Review.
- Dosimetric study between a single isocenter dynamic conformal arc therapy technique and Gamma Knife radiosurgery for multiple brain metastases treatment: impact of target volume geometrical characteristics.Chea M, Fezzani K, Jacob J, Cuttat M, Croisé M, Simon JM, Feuvret L, Valery CA, Maingon P, Benadjaoud MA, Jenny C.Radiat Oncol. 2021 Feb 27;16(1):45. doi: 10.1186/s13014-021-01766-w.PMID: 33639959 Free PMC article.
- The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases.Gutschenritter T, Venur VA, Combs SE, Vellayappan B, Patel AP, Foote M, Redmond KJ, Wang TJC, Sahgal A, Chao ST, Suh JH, Chang EL, Ellenbogen RG, Lo SS.Cancers (Basel). 2020 Dec 29;13(1):70. doi: 10.3390/cancers13010070.PMID: 33383817 Free PMC article. Review.
